Abstract:Circulation Research, Ahead of Print. BACKGROUND:Cardiac hypertrophy is an adaptive response to pressure overload aimed at maintaining cardiac function. However, prolonged hypertrophy significantly increases the risk of maladaptive cardiac remodeling and heart failure. Recent studies have implicated long noncoding RNAs in cardiac hypertrophy and cardiomyopathy, but their significance and mechanism(s) of action are not well understood.METHODS:We measuredlincRNA-p21RNA and H3K27ac levels in the hearts of dilated cardiomyopathy patients. We assessed the functional role oflincRNA-p21in basal and surgical pressure-overload conditions using loss-of-function mice. Genome-wide transcriptome analysis revealed dysregulated genes and pathways. We labeled proteins in proximity to full-lengthlincRNA-p21using a novel BioID2-based system. We immunoprecipitatedlincRNA-p21-interacting proteins and performed cell fractionation, ChIP-seq (chromatin immunoprecipitation followed by sequencing), and co-immunoprecipitation to investigate molecular interactions and underlying mechanisms. We used GapmeR antisense oligonucleotides to evaluate the therapeutic potential oflincRNA-p21inhibition in cardiac hypertrophy and associated heart failure.RESULTS:lincRNA-p21was induced in mice and humans with cardiomyopathy. Global and cardiac-specificlincRNA-p21knockout significantly suppressed pressure overload-induced ventricular wall thickening, stress marker elevation, and deterioration of cardiac function. Genome-wide transcriptome analysis and transcriptional network analysis revealed thatlincRNA-p21actsin transto stimulate the NFAT/MEF2 pathway. Mechanistically,lincRNA-p21is bound to the scaffold protein KAP1.lincRNA-p21cardiac-specific knockout suppressed stress-induced nuclear accumulation of KAP1, and KAP1 knockdown attenuated cardiac hypertrophy and NFAT activation. KAP1 positively regulates pathological hypertrophy by physically interacting with NFATC4 to promote the overactive status of NFAT/MEF2 signaling. GapmeR antisense oligonucleotide depletion oflincRNA-p21similarly inhibited cardiac hypertrophy and adverse remodeling, highlighting the therapeutic potential of inhibitinglincRNA-p21.CONCLUSIONS:These findings advance our understanding of the functional significance of stress-induced long noncoding RNA in cardiac hypertrophy and demonstrate the potential oflincRNA-p21as a novel therapeutic target for cardiac hypertrophy and subsequent heart failure.

Identification of a long noncoding RNA Gm17501 as a novel negative regulator of cardiac hypertrophy

Identification and Functional Prediction of Long Non-Coding RNAs in Dilated Cardiomyopathy by Bioinformatics Analysis

LncRNA TUG1 Alleviates Cardiac Hypertrophy by Targeting Mir‐34a/dkk1/wnt‐β‐catenin Signalling

LncRNA Gm15834 Aggravates Cardiac Hypertrophy by Interacting with Sam68 and Activating NF-κB Mediated Inflammation

lncRNA Gm20257 alleviates pathological cardiac hypertrophy by modulating the PGC-1α-mitochondrial complex IV axis

Abstract 91: Genome-wide Identification and Characterization of Cardiac Hypertrophy-related Long Noncoding RNAs in Mice

The Long Noncoding RNA CARDINAL Attenuates Cardiac Translation

The H19 Long Noncoding RNA is a Novel Negative Regulator of Cardiomyocyte Hypertrophy.

lncExACT1 and DCHS2 Regulate Physiological and Pathological Cardiac Growth

Inhibition of long noncoding RNA Gm41724 alleviates pressure overload-induced cardiac fibrosis by regulating lamina-associated polypeptide 2α

Long noncoding RNA AK144717 exacerbates pathological cardiac hypertrophy through modulating the cellular distribution of HMGB1 and subsequent DNA damage response

LncRNAs in Cardiac Hypertrophy: from Basic Science to Clinical Application

Therapeutic Inhibition of LincRNA-p21 Protects Against Cardiac Hypertrophy

The function of LncRNA-H19 in cardiac hypertrophy

Long Noncoding RNA Cardiac Physiological Hypertrophy–Associated Regulator Induces Cardiac Physiological Hypertrophy and Promotes Functional Recovery after Myocardial Ischemia-Reperfusion Injury

The role of lncRNAKCNQ1OT1/miR-301b/Tcf7 axis in cardiac hypertrophy

Long non‐coding RNA cardiac hypertrophy‐associated regulator governs cardiac hypertrophy via regulating miR‐20b and the downstream PTEN/AKT pathway

The Long Noncoding RNA CHRF Regulates Cardiac Hypertrophy by Targeting Mir-489.

Altered Long Noncoding Rna Expression Profiles In The Myocardium Of Rats With Ischemic Heart Failure

LncRNA ZNF593-AS Alleviates Contractile Dysfunction in Dilated Cardiomyopathy

Long noncoding RNA H19 suppresses cardiac hypertrophy through the MicroRNA-145-3p/SMAD4 axis